Press Release

Head and Neck Cancer Therapeutics Market to Witness Healthy Growth through 2025

Increasing cases of head and neck cancer and spike in demand for combination therapy to drive global head and neck cancer therapeutics market

According to TechSci Research report, Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy and blood tests, Imaging, Endoscopy, Others), By Treatment Type (Chemotherapy, Surgery, Radiation Therapy (External Radiation Therapy, Internal Radiation Therapy), Targeted Therapy, Immunotherapy), By Disease Indication (Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Others), By Route of Administration (Oral, Injectable), By Therapeutic Class (PD Inhibitors, Microtubule Inhibitors, EGFR Inhibitors), By  End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025, the market is anticipated to witness robust CAGR during the forecast period. The growth in global head and neck cancer therapeutics market can be attributed to rising prevalence of head and neck cancer around the world and growing geriatric population, which is more vulnerable to cancer. According to Union for International Cancer Control (UICC), around 300,000 deaths happen every year due to head and neck cancer. This is leading to growing awareness and increasing demand for head and neck cancer therapeutics. In addition to this, extensive R&D activities to develop ideal therapeutic and growing demand for combination therapies to treat head and neck cancer are expected to augment the market growth through 2025.

Moreover, governments and private organizations’ initiative to provide improved healthcare service and beneficial healthcare reforms are supporting the growth of global head and neck cancer therapeutics market. Also, growing popularity of immunotherapy for head and neck cancer treatment is expected to provide huge growth opportunities for pharmaceutical companies. Furthermore, cancer awareness programs and early cancer diagnosis are acting as some other key growth drivers for head and neck cancer therapeutics market.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global Head and Neck Cancer Therapeutics Market"

https://www.techsciresearch.com/report/head-and-neck-cancer-therapeutics-market/5056.html

 

The global head and neck cancer therapeutics market is segmented based on diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user and region. Based on disease indication, the market can be segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer and others. Among them, lip and oral cavity cancer is expected to contribute largest share through 2025 due to large patient pool affected by lip and oral cancer globally.

Based on therapeutic class, global head and neck cancer therapeutics market can be segmented into PD inhibitors, microtubule inhibitors and EGFR inhibitors. Among them, PD inhibitor drug class is expected to grow significantly during the forecast period owing to new product launches.

Major players operating in the global head and neck cancer therapeutics market include AstraZeneca Plc., Acceleron Pharma, Inc., Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Bayer AG and AbbVie Inc. The players are undergoing extensive R&D activities to develop new therapeutic drugs and increase their global market share.

Download Sample Report  @ https://www.techsciresearch.com/sample-report.aspx?cid=5056

Customers can also request for 10% free customization on this report.

“North America is expected to contribute to largest share in global head and neck cancer therapeutics market as United States is witnessing high prevalence HPV-induced cancers. However, Asia Pacific is expected to register fastest CAGR during the forecast period owing to rising incidences of head & neck cancer. The risk factors such as increase in cigarette smoking and usage of tobacco is also making the region a lucrative market for drug manufacturing companies,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy and blood tests, Imaging, Endoscopy, Others), By Treatment Type (Chemotherapy, Surgery, Radiation Therapy (External Radiation Therapy, Internal Radiation Therapy), Targeted Therapy, Immunotherapy), By Disease Indication (Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Others), By Route of Administration (Oral, Injectable), By Therapeutic Class (PD Inhibitors, Microtubule Inhibitors, EGFR Inhibitors), By  End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global head and neck cancer therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global head and neck cancer therapeutics market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

 

Tel: +1-646-360-1656

 

Email: [email protected]

Relevant Reports

Relevant News